A narrative audit of Subsense.

Section 1

What the press is doing

Most of your coverage is one of two things.

Half of what's been written about Subsense is a rewrite of a Business Wire release. About a quarter is original reporting from a small group of trade journalists. Three pieces in the whole 14-month window actually engage with the technology, and one of them is by the CEO of a competing BCI startup.

Press coverage clusters around the funding announcements and goes mostly quiet between them. Between February and December 2025 there were a handful of conference appearances and one Forbes newsletter item. That's normal for a seed-stage company, but it's worth naming what fills those gaps: the people writing about BCI keep writing about BCI, and the category language they end up using is whatever language is most readily available. Right now that isn't yours.

Where Neuralink shows up in your articles.

Seven of twenty articles name Neuralink before they name you, usually as the category reference point. One headline, in CTOL Digital, calls Subsense a “Neuralink alternative” outright. The other ten don't mention Neuralink at all, usually because they're rewrites of your press releases and your press releases don't bring it up.

The takeaway isn't that Neuralink is looming. It's that Neuralink shows up by default whenever a journalist does original reporting, because they need a category reference and you haven't given them another one. The press releases stay quiet on Neuralink, the features pull it in. Both come from the same root cause.

What words the press uses for what you do.

The vocabulary the press is using is the same vocabulary Sam Altman has now started using for Merge Labs. “Non-surgical BCI” already overlaps with his pitch, and his pitch comes with more capital and more attention than yours. There's probably a 6–12 month window before that label belongs to him.

What I'd argue about this.

“Bioplatform” appears on your homepage and your tech page. It's the most distinctive word in your own materials, and in 14 months no outside journalist has picked it up.

My guess is that the word shows up on your site without a definition attached. “Non-surgical, nanoparticle-based BCI” is on the press releases and explains itself in five words. “Bioplatform” requires the journalist to write the definition themselves, and on deadline they're going to default to whatever's already explained for them.

What I'd do is write the definition once, put it at a fixed URL, and link to it from every press kit. Something along these lines:

The transience point is what survives the Merge Labs collision. Their gene therapy is permanent; yours clears in a couple of months. For a patient deciding whether to sign up for a trial, that's a meaningful difference, and right now your public materials don't say it anywhere.

The practical first step would be to walk the four reporters who've actually done original work on Subsense (Jim Hammerand at Medical Design & Outsourcing, Sean Whooley at MassDevice, Eleanor Garth at Longevity Technology, and the team at Citeline / Medtech Insight) through the new definition before the next news beat, and have the next press release lead with it.

Section 2

What your own materials do

Your website says four different things.

I went through every page on subsense-bci.com and pulled the primary self-descriptions. There are four of them in active rotation:

The December 2025 press release opens with the phrase “non-surgical invasive, nanoparticle-based brain-computer interfaces.” That construction got picked up verbatim by multiple outlets.

A journalist who lands on your site looking for one canonical description leaves with four to choose from. They pick the simplest one, almost always “non-surgical BCI,” because they're on deadline and that one explains itself.

What I'd argue about this.

Settle on one sentence and use it everywhere: every page on the site, every release, every interview opener. Then keep using it until you start hearing it back from outside.

The sentence I'd argue for is the Bioplatform definition from above, compressed:

Subsense is a Bioplatform — a modular neural interface built from biocompatible nanoparticles that temporarily configure the brain as its own interface, then clear.

This is editorial discipline more than strategy. A day of work, probably even less. The reason it hasn't happened isn't that it's hard; it's that nobody on the team has had it as their actual job. If a starting draft would be useful, I'd be glad to put one together for you to react to.

Section 3

What your interviews do

You've done a lot of media. It hasn't compounded.

You've been on DeviceTalks Weekly, Longevity Technology, Medical Design & Outsourcing, MedicalExpo, Decrypt, Cruxx, State of Medtech, the San Francisco Experience, plus TEDx, DeviceTalks West, Neurotech Leaders Forum, and JPM. That's a lot.

Each interview reads well on its own, but they don't add up to a single picture. To Medical Design & Outsourcing you said “moonshot.” To Cruxx, “third way.” To DeviceTalks, “Bioplatform.” The stealth quotes used “limitless human potential.” The December release used “bio-integrated.” Five different framings in 14 months, all of them yours, none of them repeated. If a journalist reads two of these interviews back-to-back, the company they're describing in their head won't be quite the same company.

The strongest things you've said are in the smallest rooms.

A non-comprehensive list of your strongest quotes from the audit:

• It is invasive in interaction but non-surgical in procedure. It creates a new space between the two. It is a third way. Cruxx, February 2026
• We won't have any more phones, any laptops, we will just have everything in our heads, communicating wirelessly. I hope the world is waiting. Longevity Technology, April 2025
• Maybe it's bold to say, but 80%, maybe 70% of something that already is executing, we can cover it better… because of the nonsurgical approach. Medical Design & Outsourcing, September 2025
• We are challenging the assumption that effective and highly accurate neuromodulation must require permanently implanted hardware. LinkedIn

The Cruxx quote is the sharpest line in the whole audit, and Cruxx is a recruiter platform read mostly by MedTech executives looking for jobs. The Longevity Technology quote is the most evocative thing you've said as a founder, and Longevity Technology is a small specialist publication on aging research. Neither outlet is read by the science journalists at WSJ, STAT, or Nature.

Where the BCI conversation actually happens.

When CNBC, Bloomberg, Nature, and CB Insights write up the BCI competitive landscape, you're not on the list. The canonical 2025–26 peer set is Neuralink, Synchron, Paradromics, Precision, Science Corp, Blackrock, and Merge Labs. Subsense isn't in it.

The journalists writing those landscape pieces pull their peer sets from the X discourse, where Hodak and Angle and Oxley are posting weekly. You aren't posting at all, so the simplest available signal (is this person operating in the same conversation as the rest of the field?) comes up negative.

What I'd argue about this.

The volume isn't the issue. The language is too scattered, that's the issue. What I'd suggest is picking a small number of places to be consistent in and saying the same things in all of them every week, for long enough that the phrasing starts to spread.

A few places worth being on:

X, under your name, not the company account. One substantive post a week, no exceptions. Technical clarifications, responses to industry posts, a plain-language take when there's news in the field. This is the feed CNBC and Bloomberg journalists scan when they're deciding who counts as a category participant. You're not in it; everyone else is.

A long-form essay home. Either a Subsense Substack or a recurring byline at Technology Networks, where you already have an editor page. Roughly one essay a quarter. Each one walks the reader through the Bioplatform definition from a different angle. If it'd be helpful, I'd be glad to draft a first essay or sketch out what a Subsense Substack would look like, so you have something concrete to react to rather than a blank page.

Naveen Rao. This is the single biggest piece of unused leverage in your stack right now, and worth its own section.

Section 4

The one thing I'd do first

Naveen Rao.

Naveen Rao runs Neurotech Futures, the most-read independent newsletter on BCI (4,000+ paid subscribers). He's a Forbes contributor. He's the analyst that tier-1 journalists cite when they need a quote on the BCI category.

His relationship with Subsense, traced through his own posts:

Rao has been around Subsense plenty. He's moderated your lab opening panel, posted recap videos, named you in his BCI funding analyses. What he hasn't done is publish a piece where he actually engages with the technology, and that's the one thing that would matter most.

What I'd argue for is converting the relationship into something more structured: two or three hours with him and the science team, full access to the preclinical mouse data, a draft he can push back on hard, and a publication slot timed to the next preclinical milestone. What comes out the other end is a 3,000–4,000-word Rao-bylined piece on Neurotech Futures: the first serious technical write-up of nanoparticle BCIs that isn't written by Subsense or by someone competing with Subsense.

A piece like that does several things at once. It moves Rao from skeptical to engaged on the technical merits. It gives tier-1 journalists a citable analytical source they don't currently have, so the next time CNBC writes a BCI landscape piece, that's the document they lean on. And it raises the floor on Subsense's own public language, because once Rao has published something precise about the technology, anything Subsense says publicly afterward has to clear the same bar.

The other reason this matters: the most widely read explainer of your technology category right now is a Substack post by Aryan Govil, CEO of the competing non-invasive BCI startup Synaptrix Labs. Govil is respectful about Subsense, but his frame is “fact or fiction?” A Rao piece would be the first serious analytical account of your technology that isn't coming from you or from a competitor.